IDENTIFICATION OF SMALL-MOLECULE CANDIDATE THERAPEUTICS CAPABLE OF INHIBITING OR INTERFERING WITH A TARGET PROTEIN-PROTEIN INTERACTION
The present invention provides a method of screening method small-molecule candidate therapeutics capable of inhibiting or interfering with intracellular protein-protein interactions, such as cancer associated oncogenic protein interactions and in particular RAS and LMO2 protein-protein interactions. The present invention also provides methods and assays for rationalized drug design based on identifying small molecular weight protein-protein interaction inhibitor molecules that emulate antibody therapeutics products.
1 . A method of identifying a small-molecule candidate therapeutic capable of inhibiting or interfering with a target protein-protein interaction, the method comprising:
(i) identifying a high affinity intracellular single variable domain or antibody fragment that is associated with a protein-protein interaction, blockade of which has an effect on a disease or has an adverse biological effect;
(ii) determining contact residues involved in the protein-protein interaction between target protein and the high affinity intracellular single variable domain or antibody fragment;
(iii) engineering a derivative of the high affinity intracellular single variable domain that has a de-matured affinity for binding to the target as compared with the starting variable domain;
(iv) contacting the engineered de-matured lower binding affinity intracellular single variable domain with small-molecule candidate therapeutics and;
(v) determining binding partner(s) of the de-matured lower binding affinity intracellular single variable domain so as to identify candidate therapeutic(s).
2 . The method according to claim 1 , wherein the target protein-protein interaction is critical to the disease or adverse biological effect and is between endogenous proteins or proteins from pathogens.
3 . The method according to claim 1 , wherein the protein-protein interaction involves a cancer-associated oncogenic protein.
4 . The method according to claim 1 , wherein the high affinity intracellular variable domain or antibody fragment has a binding affinity in the nanomolar range.
5 . The method according to claim 1 , wherein the engineered derivative has a de-matured affinity for the target protein of between 10-100 times less than with the starting variable domain.
6 . The method according to claim 1 , wherein the high affinity intracellular single variable domain or antibody fragment is identified by intracellular antibody capture technology or a method suitable for selecting antigen-specific antibody fragments.
7 . The method according to claim 1 , wherein the key contact residues of an antigen-antibody complex heterodimer in step (ii) are determined by hot spot analysis of CDRs.
8 . The method according to claim 1 , wherein de-maturation of step (iii) comprises mutation of the key contact residues.
9 . The method according to claim 8 wherein, the mutation is by sequential glycine and/or alanine scanning.
10 . The method according to claim 1 , wherein the engineered de-matured lower binding affinity intracellular single variable domain has a binding affinity in the mM to μM range.
11 . A method of screening a small-molecule chemical library using at least one de-matured single domain for identifying small-molecule emulators of an antibody fragment binding site wherein the de-matured molecule has a binding affinity in the range of mM to μM.
12 . The method according to claim 11 , wherein the de-matured single domain has a binding affinity around 0.1 to 100 μM.
13 . A method of screening a small-molecule chemical library using at least one de-matured single domain for identifying small-molecule emulators of an antibody fragment binding site wherein the de-matured molecule has a binding affinity in the range of millimolar to micromolar.
14 . A binding assay for identifying inhibitors of RAS protein-protein interactions, the assay comprising a de-matured anti-RAS single domain target and an activated RAS-GTP form.
15 . The binding assay according to claim 14 , wherein the de-matured anti-RAS single domain target carries a combined mutation with T28A/S30A/T31A on CDR1 and R100G/F101G on CDR3.